Healthcare / BiotechnologyNasdaqGS
$6.46
+0.29 (+4.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-174.1M · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.1%
↓Gross Margin
N/A
•Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+36.5%
FCF CAGR
—
FCF margin
-231.7%
FCF / Net income
1.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $75.1M · net income $-146.4M · FCF $-174.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $75.1M | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M | $11.6M |
| Net Income | $-146.4M | $-146.4M | $-162.9M | $-146.4M | $158.5M | $153.5M | $118.9M | $-2.2M |
| EBITDA | $-174.4M | $-174.4M | $-204.1M | $-192.2M | $260.2M | $218.9M | $160.9M | $-2.5M |
| EPS | -0.49 | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 | 0.45 | -0.01 |
| Gross Margin | — | — | 100.0% | 100.0% | 86.3% | — | — | — |
| Operating Margin | -270.5% | -270.5% | -1044.4% | -586.6% | 46.8% | 54.5% | 66.9% | -35.5% |
| Net Margin | -194.9% | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% | -19.0% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.15 | 0.15 | 0.06 | 0.07 | 0.07 | — | — | — |
| Current Ratio | 14.05 | 14.05 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-174.1M | $-174.1M | $-187.0M | $-120.8M | $204.7M | $186.1M | $13.0M | $-1.3M |
| Returns | ||||||||
| ROE | -15.1% | -15.1% | -15.4% | -12.7% | 12.9% | 15.0% | 14.3% | -21.6% |
| Valuation | ||||||||
| P/E | — | — | — | — | 19.02 | — | — | — |
| EV/EBITDA | — | — | — | — | 10.34 | — | — | — |
| P/B | 2.00 | 2.00 | 0.87 | 1.47 | 2.43 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 160.6% | 160.6% | -24.2% | -92.2% | — | 60.9% | 1907.9% | — |
| EPS Growth | 10.9% | 10.9% | -7.8% | -202.0% | — | 6.7% | 4600.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+219.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.55 → -0.49
Residual
+219.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.